On January 9, Eisai (China) Pharmaceutical*** announced that Leyibao (lecanemab), an innovative drug for Alzheimer's disease (AD), has been approved by the National Medical Products Administration (NMPA) to enter China for mild cognitive impairment caused by Alzheimer's disease and mild dementia due to Alzheimer's disease.
As the world's first breakthrough targeted drug for Alzheimer's disease**, the approval of Leyibao will lead Alzheimer's disease** into a new era of "cause**".
Professor Chen Xiaochun, chief physician of the Department of Neurology affiliated to Fujian Medical University, said: "Lecanemab regulates the abnormal aggregation of pathological proteins by directly intervening in the causative culprit of Alzheimer's disease. Data from the Phase III global multicenter clinical study of lecanemab published in the New England Journal showed that the drug showed significant efficacy and good safety profile, with a significant reduction in A-burden after 3 months of administration and an effective 27% alleviation of disease progression in 18 months60% of patients with earlier stages achieved reversal of the course of the disease, which helped early AD patients improve cognitive impairment and maintain a longer independent life time, thereby reducing the burden on families and social economy, and also opened up a new idea for clinicians. ”
Professor Chen Xiaochun said that the clinical application of lecanemab needs to grasp the key window period of early Alzheimer's disease, and only in this way can more patients benefit from it. Compared with the previous elimination method, the current biomarker diagnosis system, such as PET-CT, cerebrospinal fluid examination, and peripheral blood detection, has significant advantages, one is to improve the sensitivity and specificity of diagnosis, and the other is to make early diagnosis of Alzheimer's disease possible.